

Curriculum Vitae

Debra, A Patt, MD MPH MBA **Medical Oncology and Hematology**

Personal Information

[REDACTED]

Primary Appointment

Vice President Public Policy and Academic Affairs, Texas Oncology
Medical Oncologist, Texas Oncology Cancer Center, Austin Texas
Medical Director, Pathways Task Force, McKesson Specialty Health/The US Oncology Network
Medical Director, Publications and Outcomes, McKesson Specialty Health
Medical Director, Breast Cancer Committee Seton Family of Hospitals

Past Appointments:

2008-2015 Medical Director Healthcare Informatics The US Oncology Network and McKesson Specialty Health

Education

Graduate:

MBA, McCombs School of Business
University of Texas at Austin
May 2014

PhD in Health Economics
University of Texas School of Public Health
anticipated graduation December 2016

MPH in Health Policy and Health Services Organization
University of Texas School of Public Health
May 2006

Fellowship:

MD Anderson Cancer Center
Fellowship in Hematology and Medical Oncology
Houston Texas
Division of Cancer Medicine
July 2003-August 2006

National Cancer Institute
Fellowship in Cancer Prevention
National Institute of Health
Rockville, Maryland
July 2005-August 2005

Residency: Baylor College of Medicine
Residency in Internal Medicine and Pediatrics
Department of Medicine and Pediatrics
Houston, Texas
June 1999-July 2003

Medical School: M.D.
Baylor College of Medicine
Houston, Texas
August 1995-June 1999.

Undergraduate: B.S. Zoology Plan I Honors Program
University of Texas at Austin
Austin, Texas
August 1992-May 1995

Licensure and Board Certifications

2003 Texas
2003 American Board of Internal Medicine
2006 American Board of Internal Medicine, Oncology specialty examination
2007 American Board of Internal Medicine, Hematology specialty examination

Professional Societies and Memberships

2004-present American Society of Clinical Oncology
2009-2015 Texas Medical Association Committee on Cancer (Chair 2011-2013)
2015-present Texas Medical Association Committee on Science and Public Health
2013 American Society of Clinical Oncology Leadership Development Program
2014-present American Society of Clinical Oncology Clinical Practice Committee (2015- Chair)
2014-present American Society of Clinical Oncology Education Committee
2014-present ASCO Payor Provider Initiative working group
2014-present ASCO Practice Policy and Emerging Issues working group
2015-Present Community Oncology Alliance- (Board Member 2016-Present)

Hospital Appointments

Seton Medical Center, Austin Texas
Seton Northwest Hospital, Austin Texas
Round Rock Medical Center, Round Rock Texas
St. David's Medical Center, Austin Texas
South Austin Hospital, Austin Texas
Brackenridge Hospital, Austin Texas
North Austin Medical Center, Austin Texas
Heart Hospital, Austin Texas

Primary Research Interests

Health Services Research
Health Economics Outcomes Research
Health Policy
Breast Cancer

Presentations at National Meetings

Patt D. Using Electronic Health Records to Improve the Quality of Cancer Care. Value-Based Oncology Management October 14-15 2015 Oral Presentation

Patt D “The Power of Partnership” Collaboration and Drug Discovery” The Economist War on Cancer September 2015. Oral Presentation

Patt D “Trends in healthcare following the ACA” The Future of Breast Cancer July 2015. Oral presentation

Espirito J, Turnwald B, Harrell R, Bhowmik D, Denduluri N, Brooks B, Hoverman R, Beveridge R, Patt D. “Bridging to Survivorship in Breast Cancer-How BMI Weigh In?” ASCO Annual Meeting June 2013. Poster Presentation.

Reeder-Hayes K, Felip E, Patt D, Jaffee E. “Women in oncology” ASCO Annual Meeting June 2013. Oral Presentation in Educational Session.

Patt D, Espirito J, Turnwald B, Harrell R, Bhowmik D, Denduluri N, Brooks B, Hoverman R, Beveridge R “Bridging to Survivorship in Breast Cancer-Learning how Treatment Impacts Mental Health”. ASCO Annual Meeting June 2013. Poster Presentation.

Patt, D “How to implement survivorship care programs in community oncology practice” Community Oncology National Practice Summit April 2013. Oral Presentation.

Patt D, Espirito J, Turnwald B, Denduluri N, Wang Y, Asmar L, Hoverman J, Neubauer M, Bosserman L, Busby L, Brooks B, Cartwright T, Sitarik M, Schnadig I, Winter W, Garey J, Ginsburg-Arlen A, Bergstrom K, Beveridge R “Cardiac morbidity after adjuvant chemotherapy for early breast cancer in the community setting” San Antonio Breast Cancer Symposium, December 2012. Poster Presentation.

Trageser J, Ahmad A, Rush M. Kahng H, Schwartz R, Arlen-Ginsburg A, Beveridge R, and Patt D “Use of a virtual collaboration tool to improve communication, education, and quality of care across a large network of oncology practices.” ASCO Quality Care Symposium November 2012. Poster Presentation

Mikan S, Hoverman R, Patt D, Turnwald B “My Choices, My Wishes: Advance Care Planning Advocacy in the Adult Oncology Population” ASCO Quality Care Symposium November 2012. Poster Presentation.

Espirito JL, Ginsburg Arlen A, Garey JS, Sheth S, Turnwald B, Clayton M, Flinn J, Butler-Dorian C, Nelson G, Hoverman JR, Patt D, Cartwright TH, Busby LT, Beveridge R, Neubauer M “Quality improvement program increases performance with clinical oncology pathways” ASCO Quality Care Symposium November 2012. Oral and Poster Presentation

Patt, D, Nubie, M., Kazzaz, D, Armen, A, Sitarik, M, Ahmad, A, Busby, L, Beveridge, R.
“Clinical decision support can improve quality and practice efficiency across a large network of oncology practices” ASCO Quality Care Symposium November 2012. Poster Presentation

Lindsey, G, Hoverman, J, Patt, D, Jastremski, D, Turnwald, B, Espirito, J, Garey, J, on behalf of the Texas Oncology Quality Committees
“Utilizing network quality committees improves reporting and adherence to evidence based clinical pathways” ASCO Quality Care Symposium November 2012. Poster Presentation

Denduluri, N, Espirito, J, Turnwald, B, Wang, Y. and Patt, D. Risk of Acute Myelogenous Leukemia and Myelodysplastic Syndrome After Adjuvant Chemotherapy for Early Breast Cancer in the Community Setting. ASCO Breast September 2012. Oral Presentation

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Busby L, Brooks B, Kolodziej M, Anderson R, Beveridge R. “Primary and secondary pegfilgrastim utilization in adjuvant chemotherapy for breast cancer in the community” SABCS December 2011. Poster/Discussion

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Busby L, Brooks B, Sitarik M, Kolodziej M, Beveridge R. “Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community” Poster Presentation
ASCO June 2012

Hoverman, J., Mikan, S. & Patt, D. (March 2012). “Octogenarians: Oncology Outcomes for Advanced Cancers in Central Texas” Aging and Society Conference 2012.

Mikan, S. & Patt, D. “Advanced Care Planning Metrics and Strategies for Improved Utilization in the Oncology-Setting”. 7th International Nurse Practitioner/Advanced Practice Nursing Network Conference: Advanced Nursing Practice: Global Vision – Global Reality. London, England February 2012.

Mikan, S., Patt, D. & Hoverman, J. R. “Identification of Advance Care Planning Metrics for Stage IV Cancers and Strategies for Improved Utilization in the Oncology-setting”. The 3rd International Society of Advance Care Planning & End of Life Care Annual Conference. Chicago, IL January 2012

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Busby L, Brooks B, Kolodziej M, Anderson R, Beveridge R. “Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community” ASCO Breast Cancer Symposium September 2011.

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Busby L, Brooks B, Sitarik M, Kolodziej M, Clayton M, Nelson G, Anderson R, Beveridge R. “Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community” ASCO 2011 Poster Presentation

Chen C, Patt d, Kazzaz D, Shankleton J, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer
ASCO MEETING ABSTRACTS Jun 9, 2011:625. Poster presentation

Ginsburg A, Patt D, Flinn J, Espirito J, Neubauer M, Cartwright T, Hoverman J, Busby L, Brooks B, Kolodziej M, Sitarik M, Anderson R, Beveridge R. "Understanding male breast cancer in the community setting."
ASCO MEETING ABSTRACTS Jun 9, 2011:e16526

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Brooks B, Busby L, Sitarik M, Kolodziej M, Ginsburg A, Sheth S, Garey J, Claytoon M, Nelson R, Anderson R, Beveridge R. "Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community"
ASCO MEETING ABSTRACTS Jun 9, 2011:e16595. Published in JCO supplements

Patt DA, Espirito J, Turnwald B, Hoang S, Hoverman J. "Ixabepilone alone and in combination with chemotherapy in the community setting" ASCO Breast Abstract 204, 2010. Poster presentation

Patt D, Goodwin J, Kuo Y, Freeman J, Zhang D, Buccholz T, Hortobagyi G, Giordano S. "Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk"
ASCO Annual meeting, 2006. Poster Presentation

Patt D, Goodwin J, Kuo Y, Freeman J, Zhang D, Buccholz T, Hortobagyi G, Giordano S. "Cardiac morbidity of adjuvant radiotherapy for breast cancer" San Antonio Breast Cancer Symposium, 2004. Poster Presentation

Publications

Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1383-93.

Yasenchak CA, Tseng WY, Yap M, Rembert D, Patt DA. "Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma." *Leuk Lymphoma* 2015 May 18. 1-7

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. "Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma" *J Clin Oncol* 2015 Feb 9. [Epub ahead of print] PMID:25667295

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, **Patt DA**, Perez EA, Perlmutter J, Winer EP, Lin NU. "Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline." *J Clin Oncol*. 2014 May 5. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/24799487>

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, **Patt DA**, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. "Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology

Clinical Practice Guideline.” *J Clin Oncol*. 2014 May 5. [Epub ahead of print]<http://www.ncbi.nlm.nih.gov/pubmed/24799465>

Patt DA “Taking on racial and ethnic disparities in cancer care” *J Community and Supportive Oncology* 2014 111-112.

Reeder-Hayes K, Felip E, Patt D, Jaffee E. “Women in oncology” *Am Soc Clin Oncol Educ. Book* 2013;448-55. 2013

Ramsey SD, Sullivan SD, Reed SD, Tina Shih YC, Schaecher K, Dhanda R, Patt D, Pendergrass K, Walker M, Malin J, Schwartzberg L, Neumann K, Yu E, Ravelo A, Small A. “Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.” *Oncologist* 2013; 18(6): 760-7. Epub May 6, 2013

Brow M, Okon T, George E, Eagle D, Patt D, Gould B, Brooks B, Cobb P, White C, Tetrault S, Beveridge R. “Thoughts and recommendations on cancer care site of service” *Community Oncology* 2012 9(2) pages 382-385.

Brow M, Hoverman JR, Patt D, Herman B, Verrilli D, Garey J, Beveridge R. “Defining cancer care quality or delivering quality cancer care?” *J Natl Compr Canc Netw*. 2013 Feb 1;11(2):121-4.

Chen, C, Dhanda, R, Tseng, W, Forsyth, M, Patt, D. “Evaluating Use Characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early stage breast cancer” *J Oncol Pract* Feb 2013

Kolodziej M, Hoverman JR, Garey JS, Espirito J, Sheth S, Ginsburg A, Neubauer MA, Patt D, Brooks B, White C, Sitarik M, Anderson R, Beveridge R. “Benchmarks for value in cancer care: an analysis of a large commercial population.” *J Oncol Pract*. 2011 Sep;7(5):301-6.

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Busby L, Brooks B, Sitarik M, Kolodziej M, Beveridge R.” Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community” *ASCO MEETING ABSTRACTS* May 30, 2012:6109. Published in JCO supplements

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Busby L, Brooks, Kolodziej, Anderson R, Beveridge R “Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community” *ASCO MEETING ABSTRACTS* Sep 30, 2011:213 Published in JCO supplements

Chen C, Patt D, Kazzaz D, Shankleton J, Forsyth M, Ganesh R. “Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer” *ASCO MEETING ABSTRACTS* Jun 9, 2011:625. Published in JCO supplements

Ginsburg A, Patt D, Flinn J, Espirito J, Neubauer M, Cartwright T, Hoverman J, Busby B, Brooks, B Kolodziej M, Sitarik M, Anderson R, Beveridge R. “Understanding male breast cancer in the community setting” *ASCO MEETING ABSTRACTS* Jun 9, 2011:e16526 Published in JCO supplements

Patt D, Espirito J, Turnwald B, Hoverman J, Neubauer M, Cartwright T, Brooks B, Busby L, Sitarik M, Kolodziej M, Ginsburg A, Sheth S, Garey J, Clayton M, Nelson R, Anderson R, Beveridge R. "Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community"

ASCO MEETING ABSTRACTS Jun 9, 2011:e16595. Published in JCO supplements

Hoverman, JR. Cartwright TH. Patt, DA. Espirito, JL. Clayton, MP. Garey, JS. Kopp, TJ. Kolodziej, M. Neubauer, M. Fitch, K. Pyenson, B. Beveridge, RA. "Pathways, Outcomes, and Costs in Colon Cancer: Retrospective evaluations in two distinct databases" Journal of Oncology Practice May 2011.

O'Shaughnessy, J. Osborne, C. Pippin, JE. Yoffee, M. Patt, D. Rocha C. Koo, IC. Sherman BM. Bradley, C. "Iniparib plus Chemotherapy n Metastatic Triple-Negative Breast Cancer" NEJM 2011 Jan 20; 364(3):205-14. Epub 2011 Jan 5.

Socinski, MA. Raju, RN. Stinchombe, T. Kocs, DM. Couch, LS. Barrera, D. Rousey, SR. Choksi, JK. Jotte, R. Patt, DA. Periman, PO. Schlossberg, HR. Weissman, CH. Wang, Y. Asmar, L. Pritchard, S. Bromund J. Peng, G. Treat, J. Obasaju, CK. "Randomized phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer" J Thorac Oncol 2010 Dec; 5(12):1963-9.

Scholl, P. Snyder, N. Patt, D. Talbott, B. "Pilomatrical carcinosarcoma" Otolaryngology-Head and Neck Surgery 2010 143, s36-37.

Patt, D, Espirito, J, Turnwald, B, Hoang, S, Hoverman, J. "Ixabepilone alone and in combination with chemotherapy in the community setting" Proceedings ASCO Breast Cancer Symposium. Abstract 204. 2010.

Neubauer, MA. Espirito, JL, Clayton, M. Patt, DA. "Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network" JCO 28:15s, 2010 (suppl; abstr 6106).

Patt D, Zhigang D, Shenying F, Hortobagyi G, Giordano S. "Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk" JCO 2007 September 1 25(25) 3871-6.

Patt, Debra and Giordano, Sharon H. "Paclitaxel in Breast Cancer" Women's Health January 2006 Jan. 2:1(11)11-21

Patt, D, Goodwin J, Kuo, Y, Freeman J, Zhang D, Buccholz T, Hortobagyi G, Giordano S. "Cardiac morbidity of adjuvant radiotherapy in patients with early stage breast cancer" JCO 2005. October 20. 23(30) 7475-82.

Patt D, Shopland D, Anderson C, Burns D, Dunnington J, Gritz E. "Trends to protect workers from job related secondhand smoke in Texas" Texas Medicine. 2005 Dec; 101 (12):50-6.

Awards

2014 Ruth Baines Young Physician of the Year Award, Travis County Medical Society

2006 American Society of Clinical Oncology Young Investigators Award- This \$40,000 competitive grant awarded to fellows and young investigators who have demonstrated excellence in research.

2006 Research Fellow of the year, MD Anderson Cancer Center

2006 American Society of Clinical Oncology Merit Award

2006 Jesse Jones Fellowship in Cancer Education and Prevention at MD Anderson Cancer Center- the annual education and prevention award given to one fellow who has demonstrated excellence in these areas.

Professional Committees:

Editorial Boards: *Journal of Clinical Oncology- Clinical Cancer Informatics-*
Editor and Chief 2016-Present
Community Oncology, Associate Editor
2012-2016
Journal of Oncology Practice, Invited Reviewer

Legislative Advocacy: Texas Medical Association- Council on Legislation 2016-present
Texas Medical Association, Committee on Science and Public
Health 2015-2016
Texas Medical Association Cancer Committee
2009-2015 Chair, 2011-2013

National Programs: ASCO Clinical Practice Committee 2014-present (2015 Chair
Elect)
ASCO Education Committee 2014-present
US Oncology National Policy Board
2011-present
Publications and Outcomes Committee McKesson Specialty
Health
Medical Director and Chair, 2011-present
Healthcare Informatics, US Oncology Network
Medical Director and Chair, 2009-present
Pathways Task Force, US Oncology Network
Medical Director (Breast Cancer), 2008-present
Clinical Research Committee for Breast Cancer, US Oncology
Network
2009-present
McKesson Specialty Health Survivorship Task Force
2011-present
McKesson Specialty Health Patient Portal working group
2011-present
McKesson Specialty Health Pharmacy and Therapeutics
Committee
2008-present
McKesson Specialty Health, Collaborative Care Committee
2011-present

Local:

Susan G Komen, Austin Board 2015-present

Shivers Cancer Foundation 2015-present

Texas Oncology Quality Review Committee
2007-present

Texas Oncology-Austin Executive Committee
2011-2015

Breast Cancer Resource Centers of Central Texas Board
2011-2014

Breast Cancer Subcommittee, Seton Family of Hospitals,
Chair, 2010-present

Medical Executive Committee, Seton Medical Center
2010-present

Advisory Board of the Texas Cancer Registry
2006-present


Seton Network Cancer Committee
2007-present

M D Anderson Cancer Center, Medical Oncology
Chief of Clinical Specialist Activities, 2004-2006

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Debra Patt, MD MPH MBA		
2. Your Title: Medical Oncologist, Texas Oncology		
3. Vice President Policy, Texas Oncology		
4. Medical Director, The US Oncology Network		
5. Chair, Clinical Practice Committee, American Society of Clinical Oncology		
6. Editor and Chief, Journal of Clinical Oncology-Clinical Cancer Informatics		
7. Board Member, Community Oncology Alliance		
8. The Entity(ies) You are Representing: The US Oncology Network American Society of Clinical Oncology Community Oncology Alliance		
9. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
10. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. None		
11. Please attach your curriculum vitae to your completed disclosure form.		

Signature



Date: 5/11/16

INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

In General. The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

(B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing. (C) The disclosure referred to in subdivision (B) shall include (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.

Please complete the form in accordance with these directions.

1. ***Name, Title, Entity(ies) (Items 1-3 on the form).*** Please provide the name and title of the witness and the entity(ies) on whose behalf the witness is testifying.
2. ***Governmental Entity (Item 4).*** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental organizations.

Grants and Contracts (Item 5). Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. For each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. For each payment or contract originating with a foreign government related to the subject matter of the hearing, please include the amount and country of origin of each. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.

3. ***Curriculum Vitae (Item 6).*** Please attach your CV to your completed disclosure form.

4. ***Submission.*** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee's rules, copies of a written statement of your proposed testimony must be submitted before the commencement of the hearing. To the greatest extent practicable, please also provide a copy in electronic format according to the Electronic Format Guidelines that accompany these instructions.